Effects of Metformin on Early Pregnancy Loss in Patients with Polycystic Ovary Syndrome (PCOS)
Abstract
Objective: To determine the outcome of metformin therapy in early pregnancy loss in women with polycystic ovary syndrome (PCOS) at Tertiary Care Hospital, Karachi. Methodology: This descriptive cross-sectional study was conducted at Department of Gynecology and Obstetrics, Civil Hospital, Karachi, from February 2021 till August 2022. Newly diagnosed pregnant women, aged age of 18-40 years, gestational age ≤ 4 weeks with polycystic ovary syndrome before pregnancy and started on metformin therapy were enrolled. Patients were started on metformin therapy (1000 mg/day) and were followed by the researcher to evaluate the occurrence of early pregnancy loss. All the relevant data of the study were entered and statistically analyzed by the IBM SPSS Statistics, Version 23. Moreover the frequency of early pregnancy loss was computed and post stratified based on effect modifiers by applying chi-square test taking p-value (0.05) Conclusion: Metformin observed to be a protective management therapy to significantly reduces the early pregnancy loss among women with PCOS, possibly by correcting IR, hyperinsulinemia, and androgen excess the key metabolic drivers of miscarriage.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 125 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.